BBT594
| Code | Size | Price |
|---|
| SYN-1225-M100 | 100 mg | Enquire |
Quantity:
| SYN-1225-M050 | 50 mg | Enquire |
Quantity:
| SYN-1225-M001 | 1 mg | £233.00 |
Quantity:
| SYN-1225-M005 | 5 mg | £467.00 |
Quantity:
| SYN-1225-M010 | 10 mg | £771.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
BBT-594
Appearance:
Solid.
CAS:
882405-89-2
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C28H30F3N7O3/c1-18(39)34-25-15-26(33-17-32-25)41-22-5-6-24-19(13-22)7-8-38(24)27(40)35-21-4-3-20(23(14-21)28(29,30)31)16-37-11-9-36(2)10-12-37/h3-6,13-15,17H,7-12,16H2,1-2H3,(H,35,40)(H,32,33,34,39)
InChiKey:
VQLNKQZLPGLOSI-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 882405-89-2. Formula: C28H30F3N7O3. MW: 569.6. BBT594 (NVP-BBT594) is a potent and selective inhibitor of RET and JAK2. BBT594 impairs "glial-derived neurotrophic factor" (GDNF)-RET signaling and GDNF-dependent growth in specific in vitro models. Direct inhibition of GDNF-RET signaling by BBT594 in ER+ breast cancer cells enhances the sensitivity to aromatase inhibitor (AI) treatment and reverts AI resistance. In murine models, the IC50 of BBT594 on JAK2 inhibition varies between 8nM - 29nM, depending on the cell model and abundant JAK2 mutations.
Molecular Formula:
C28H30F3N7O3
Molecular Weight:
569.6
Package Type:
Plastic Vial
Product Description:
BBT594 (NVP-BBT594) is a potent and selective inhibitor of RET and JAK2. BBT594 impairs "glial-derived neurotrophic factor" (GDNF)-RET signaling and GDNF-dependent growth in specific in vitro models. Direct inhibition of GDNF-RET signaling by BBT594 in ER+ breast cancer cells enhances the sensitivity to aromatase inhibitor (AI) treatment and reverts AI resistance. In murine models, the IC50 of BBT594 on JAK2 inhibition varies between 8nM - 29nM, depending on the cell model and abundant JAK2 mutations.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent: R. Andraos, et al.; Cancer Discov. 2, 512 (2012) | GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors: A. Morandi, et al.; Cancer Res. 73, 3783 (2013)
Related Products
| Product Name | Product Code | Supplier | Ruxolitinib | AG-CR1-3624 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ruxolitinib . phosphate salt | AG-CR1-3645 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bayer-18 | SYN-1130 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||